Prostate Cancer - Results from #880

REVIEW UroToday

Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer, "Beyond the Abstract," by Boris Gershman, Irene M. Shui, and Lorelei A. Mucci July 18, 2013

Lycopodine triggers apoptosis by modulating 5-lipoxygenase, and depolarizing mitochondrial membrane potential in androgen sensitive and refractory prostate cancer cells without modulating p53 activity, "Beyond the Abstract," by Kausik Bishayee July 17, 2013

Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer in Chinese men, "Beyond the Abstract," by Peng Zhang and Xiang-Yi Zheng July 17, 2013

Intratumoral acetic acid injection eradicates human prostate cancer tumors in a murine model, "Beyond the Abstract," by Jasneet Singh Bhullar, MD, MS July 15, 2013

An overview of current and emerging therapeutic management strategies for patients with metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Joelle El-Amm, MD and Jeanny Aragon-Ching, MD July 12, 2013

Vorinostat and bortezomib, an innovative treatment strategy against advanced prostate cancer - ready for clinical trial, "Beyond the Abstract," by Masamichi Hayakawa, MD, PhD July 12, 2013

Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall, "Beyond the Abstract," by Michael Pinkawa, MD July 11, 2013

Benefit of corticosteroids in severe hepatitis induced by cyproterone acetate, "Beyond the Abstract," by Ludovico Abenavoli, MD, MSc, PhD July 11, 2013

Death by association: A peptidic unconjugated GRP78/BiP ligand modulates the unfolded protein response and induces prostate cancer cell death, "Beyond the Abstract," by Danilo Maddalo and Andrew C. B. Cato July 10, 2013

Low testosterone levels predict prostate cancer: Hormonal pattern as a useful tool for prostate cancer screening, "Beyond the Abstract," by Eduard García-Cruz, MD, et al. July 9, 2013

Degarelix vs goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: Results from a phase IIIb study (NCT00831233) - Abstract, "Beyond the Abstract," by Bo-Eric Persson, MD July 8, 2013

Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer, "Beyond the Abstract," by John J. Kim, Kenneth J. Pienta and Steven M. Mooney July 1, 2013

Association between glomerular filtration rate and percent-free prostate-specific antigen in transrectal ultrasound-guided biopsy-proven patients with prostate-specific antigen levels ranging from 4 to 10 ng/ml, "Beyond the Abstract," by Jae Young Park June 28, 2013

An educational intervention for patients on androgen deprivation therapy and their partners, "Beyond the Abstract," by Lauren M. Walker, et al June 21, 2013

Bone scan is of doubtful value as a first staging test in the primary presentation of prostate cancer, "Beyond the Abstract," by Lina M. Carmona June 20, 2013

CCL11 (eotaxin-1): A new diagnostic serum marker for prostate cancer, "Beyond the Abstract," by Jill A. Macoska, PhD June 19, 2013

Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: Results from a baseline analysis in the Canary Prostate Active Surveillance Study, "Beyond the Abstract," by Lisa Newcomb and Daniel W. Lin June 18, 2013

Ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments, "Beyond the Abstract," by Robert J. Amato, DO June 18, 2013

A discussion of the value and benefit of transrectal power Doppler sonography for detecting low-risk prostate cancers, "Beyond the Abstract," by J.-L. Sauvain, and E. Sauvain June 15, 2013

Application and clinical benefits of degarelix, a GnRH antagonist, in the treatment of advanced prostate cancer, "Beyond the Abstract," by Neal D. Shore, MD, FACS June 13, 2013

Page 45 of 57